Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2020
LYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary Avenant au Contrat de Liquidité
ERYTECH : Avenant au Contrat de Liquidité March 26, 2014 03:00 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )--Regulatory News: ERYTECH (Paris:ERYP) (Euronext Paris : FR0011471135 - ERYP), société biopharmaceutique française qui conçoit des traitements innovants contre les leucémies
View HTML
Toggle Summary Bilan semestriel du contrat de liquidité confié à la société de bourse Bryan, Garnier & Co.
ERYTECH Pharma : Bilan semestriel du contrat de liquidité confié à la société de bourse Bryan, Garnier & Co. July 02, 2014 12:00 PM Eastern Daylight Time LYON, France--( BUSINESS WIRE )--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris : FR0011471135 - ERYP), société biopharmaceutique
View HTML
Toggle Summary CORRECTING and REPLACING: Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital
December 2015 Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Feb. 4, 2016-- Regulatory News: This replaces the announcement made at 2:20 pm on January 12 due to the following corrections: The total of brut voting rights of 9 625 437 is
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Nov 5, 2020

Business Update and Financial Highlights for the 3rd Quarter of 2020 (after U.S. market close)

Summary Toggle Nov 6, 2020 at 8:30 AM EST

Erytech Pharma 3rd Quarter of 2020 Conference Call and Webcast

Summary Toggle Nov 17 - Nov 19, 2020

Jefferies Health Care Conference, Virtual

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top